{
  "drug_name": "rofecoxib",
  "nbk_id": "NBK470306",
  "url": "https://www.ncbi.nlm.nih.gov/books/NBK470306/",
  "scraped_at": "2026-01-11T15:38:01",
  "sections": {
    "clinical_significance": "From a clinical perspective, the physiological roles and therapeutic implications of endorphins remain under active investigation. One important pharmacological interaction involves naloxone, an opioid antagonist commonly used to reverse opioid overdose. Naloxone competitively binds to opioid receptors, displacing both exogenous opioids and endogenous ligands such as endorphins. This antagonism not only blocks opioid-induced respiratory depression but can also inhibit normal endorphin signaling. Interestingly, naloxone has demonstrated therapeutic potential in conditions such as depersonalization disorder, where administration of the drug has led to symptomatic improvement. This observation suggests a possible role for dysregulated endorphin activity in the pathophysiology of dissociative disorders.\n\nAnother clinically significant area of study concerns the relationship between chronic opioid dependence and hypothalamo-pituitary-gonadal axis dysfunction. Evidence indicates that β-endorphins influence luteinizing hormone secretion from the anterior pituitary by modulating gonadotropin-releasing hormone. Chronic opioid use can disrupt this regulatory pathway, leading to reduced gonadal hormone production and subsequent reproductive dysfunction, an increasingly recognized complication of long-term opioid therapy.\n\nModulation of β-endorphin levels by different classes of analgesics has raised important questions regarding their role in pain perception and treatment efficacy. Studies in postsurgical patients comparing opioid and nonopioid analgesics have shown that β-endorphin levels increase significantly following opioid administration, reflecting both physiological pain responses and drug-induced enhancement. Interestingly, acetaminophen appears to suppress β-endorphin levels, whereas the COX-2 inhibitor rofecoxib does not, despite its effective analgesic action. These findings suggest that certain nonopioid analgesics can achieve pain relief without interfering with endogenous opioid pathways, opening avenues for developing safer alternatives that avoid opioid-associated risks such as tolerance, dependence, and addiction.\n[14]\n[15]"
  }
}